NCI-H2126 Cells

The NCI-H2126 cell line is derived from a human large cell carcinoma, a subtype of non-small cell lung cancer (NSCLC). Originating from the lung tissue of a male patient, this cell line exhibits characteristics typical of large cell carcinomas, including poorly differentiated, undifferentiated cellular features. It is an important model for understanding the genetic and molecular mechanisms underlying large cell lung cancers and for testing therapeutic agents targeting this NSCLC subtype. Genomic studies on NCI-H2126 have identified frequent allelic losses and chromosomal aberrations, such as deletions on chromosome arms 6q and 13q, which are commonly implicated in tumor suppressor gene inactivation in NSCLC. These genetic alterations contribute to the disruption of key regulatory pathways, including those involved in cell cycle control and apoptosis. The cell line has been employed in comparative studies to distinguish patterns of chromosomal loss across different lung cancer subtypes, enhancing the understanding of NSCLC-specific molecular signatures. NCI-H2126 has also been included in extensive drug screening programs to evaluate its sensitivity and resistance to various chemotherapeutic agents and targeted therapies. The cell line’s genetic profile and its tumorigenic potential in xenograft models make it a valuable resource for preclinical studies focused on the development and refinement of treatments for large cell carcinoma and other forms of NSCLC.